ROCKVILLE, Md., May 20, 2014 /PRNewswire/ -- Synthetic
Biologics, Inc. (NYSE MKT: SYN), a developer of anti-infective
biologic and drug candidates targeting specific pathogens that
cause serious infections and diseases, announced today that
Jeffrey Riley, CEO, is scheduled to
present at the 3rd Annual Marcum LLP MicroCap Conference
on Thursday, May 29, 2014 in
New York City at the Grand Hyatt
Hotel. Mr. Riley is scheduled to present at 4:30 p.m. (Eastern Time).
A live webcast of Synthetic Biologics' presentation can be
accessed by logging onto the web at
http://wsw.com/webcast/marcum2/syn. After the presentation, a
replay will be archived and accessible for 60 days at the same
website.
Mr. Riley, as well as Synthetic Biologics' CFO, C. Evan Ballantyne, will be available to
participate in one-on-one meetings with investors and analysts who
are registered to attend the conference. Please contact the Marcum
conference representative Taline
Chalian at taline.chalian@marcumllp.com.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology
company focused on the development of novel anti-infective biologic
and drug candidates targeting specific pathogens that cause serious
infections and diseases. The Company is developing an oral
treatment to reduce the impact of methane producing organisms on
constipation-predominant irritable bowel syndrome (C-IBS), an oral
biologic to protect the gastrointestinal microflora from the
effects of IV antibiotics for the prevention of Clostridium
difficile (C. difficile) infection, a series of monoclonal
antibodies for the treatment of Pertussis and Acinetobacter
infections, and a biologic targeted at the prevention and treatment
of a root cause of a subset of IBS. In addition, the Company is
developing an oral estriol drug for the treatment of
relapsing-remitting multiple sclerosis (MS) and cognitive
dysfunction in MS. For more information, please visit Synthetic
Biologics' website at www.syntheticbiologics.com.
Logo -
http://photos.prnewswire.com/prnh/20130522/MM19465LOGO
SOURCE Synthetic Biologics, Inc.